Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$18.14
At close: Jun 24, 4:00 PM EDT
$18.14
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Dianthus Therapeutics Analyst Ratings and Price Targets | NASDAQ:DNTH | Benzinga
Dianthus Therapeutics Inc has a consensus price target of $50.13 based on the ratings of 10 analysts. The high is $84 issued by Guggenheim on March 12, 2025. The low is $36 issued by Wedbush on March 12, 2025. The 3 most-recent analyst ratings were released by Baird, HC Wainwright & Co., and Wedbush on May 13, 2025, May 13, 2025, and March 12, 2025, respectively. With an average price target of $42 between Baird, HC Wainwright & Co., and Wedbush, there's an implied 131.53% upside for Dianthus Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Baird
HC Wainwright & Co.
Wedbush
Guggenheim
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Dianthus Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2025 | Buy Now | 175.63% | Baird | Joel Beatty68% | $58 → $50 | Maintains | Outperform | Get Alert |
| 05/13/2025 | Buy Now | 120.51% | HC Wainwright & Co. | Swayampakula Ramakanth53% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | 98.46% | Wedbush | Laura Chico51% | $36 → $36 | Reiterates | Outperform → Outperform | Get Alert |
| 03/12/2025 | Buy Now | 363.07% | Guggenheim | Yatin Suneja55% | $84 → $84 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | 120.51% | HC Wainwright & Co. | Swayampakula Ramakanth53% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 12/20/2024 | Buy Now | — | TD Cowen | Yaron Werber34% | — | Initiates | → Buy | Get Alert |
| 11/11/2024 | Buy Now | 120.51% | HC Wainwright & Co. | Swayampakula Ramakanth53% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | 186.66% | Oppenheimer | Leland Gershell68% | $48 → $52 | Maintains | Outperform | Get Alert |
| 11/08/2024 | Buy Now | 208.71% | Raymond James | Steven Seedhouse57% | $51 → $56 | Maintains | Outperform | Get Alert |
| 10/03/2024 | Buy Now | 164.61% | Oppenheimer | Leland Gershell68% | → $48 | Initiates | → Outperform | Get Alert |
| 09/26/2024 | Buy Now | 120.51% | HC Wainwright & Co. | Swayampakula Ramakanth53% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | 120.51% | HC Wainwright & Co. | Swayampakula Ramakanth53% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2024 | Buy Now | 98.46% | Wedbush | Laura Chico51% | $38 → $36 | Maintains | Outperform | Get Alert |
| 07/26/2024 | Buy Now | 219.74% | Baird | Joel Beatty68% | → $58 | Initiates | → Outperform | Get Alert |
| 06/27/2024 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos39% | — | Initiates | → Overweight | Get Alert |
| 05/16/2024 | Buy Now | 120.51% | HC Wainwright & Co. | Swayampakula Ramakanth53% | → $40 | Initiates | → Buy | Get Alert |
| 05/10/2024 | Buy Now | 109.48% | Wedbush | Laura Chico51% | $33 → $38 | Maintains | Outperform | Get Alert |
| 04/18/2024 | Buy Now | 181.15% | Raymond James | Steven Seedhouse57% | $34 → $51 | Maintains | Outperform | Get Alert |
| 03/22/2024 | Buy Now | 114.99% | Jefferies | Maury Raycroft33% | $22 → $39 | Maintains | Buy | Get Alert |
| 03/22/2024 | Buy Now | 81.92% | Wedbush | Laura Chico51% | $24 → $33 | Maintains | Outperform | Get Alert |
| 02/15/2024 | Buy Now | 142.56% | Stifel | Alex Thompson43% | → $44 | Initiates | → Buy | Get Alert |
| 01/26/2024 | Buy Now | 32.3% | Wedbush | Laura Chico51% | $23 → $24 | Maintains | Outperform | Get Alert |
| 12/26/2023 | Buy Now | 21.28% | Jefferies | Maury Raycroft33% | → $22 | Initiates | → Buy | Get Alert |
| 11/22/2023 | Buy Now | 26.79% | Wedbush | Laura Chico51% | → $23 | Initiates | → Outperform | Get Alert |
| 09/28/2023 | Buy Now | 32.3% | Raymond James | Steven Seedhouse57% | → $24 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Dianthus Therapeutics (DNTH) stock?
The latest price target for Dianthus Therapeutics (NASDAQ:DNTH) was reported by Baird on May 13, 2025. The analyst firm set a price target for $50.00 expecting DNTH to rise to within 12 months (a possible 175.63% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Dianthus Therapeutics (DNTH)?
The latest analyst rating for Dianthus Therapeutics (NASDAQ:DNTH) was provided by Baird, and Dianthus Therapeutics maintained their outperform rating.
When was the last upgrade for Dianthus Therapeutics (DNTH)?
There is no last upgrade for Dianthus Therapeutics
When was the last downgrade for Dianthus Therapeutics (DNTH)?
There is no last downgrade for Dianthus Therapeutics.
When is the next analyst rating going to be posted or updated for Dianthus Therapeutics (DNTH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dianthus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dianthus Therapeutics was filed on May 13, 2025 so you should expect the next rating to be made available sometime around May 13, 2026.
Is the Analyst Rating Dianthus Therapeutics (DNTH) correct?
While ratings are subjective and will change, the latest Dianthus Therapeutics (DNTH) rating was a maintained with a price target of $58.00 to $50.00. The current price Dianthus Therapeutics (DNTH) is trading at is $18.14, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
